Latest / Stock Movers / Biogen to Buy Apellis; Lilly to Buy Sleep Drug Maker; Nvidia Invests $2 Billion in Marvell
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market,
- 0:13Speaker 1: harnessing the power of Bloomberg data.
- 0:16Speaker 2: Let's take a look at some stocks in the move today.
- 0:18Speaker 2: Alexisfus it's a podcast and it's stock movers. It's a
- 0:24Speaker 2: spicy stock movers Alexis Stock. Yeah, I like that spicy.
- 0:28Speaker 2: I'm going to start with a spicy want, Appellas Pharmaceuticals
- 0:31Speaker 2: because this stock has more than doubled here in the
- 0:33Speaker 2: pre market. It's up one hundred and thirty six percent.
- 0:36Speaker 2: And here's why.
- 0:38Speaker 3: Biogen is going to buy a Pelas for forty one
- 0:41Speaker 3: dollars a share. That's more than double the company's closing
- 0:44Speaker 3: price yesterday. Before this deal, A Pelas's stock was down
- 0:48Speaker 3: thirty two percent. So in this bio Biogen's going to
- 0:51Speaker 3: get two approved drugs. Appelas's best selling medicine that treats
- 0:55Speaker 3: an immune disorder that's a leading cause of blindness. That
- 0:58Speaker 3: drug generated more than half a billion dollars in revenue
- 1:00Speaker 3: last year, and another drug that treats both a blood
- 1:03Speaker 3: disorder and a rare kidney disease. And we know that
- 1:06Speaker 3: Biogen has really been focusing on kidney disease. It's been
- 1:09Speaker 3: an area of focus for the company. So Biogen says
- 1:12Speaker 3: this deal is going to provide some near term revenue
- 1:14Speaker 3: growth that it fits with its strategy. And the CEO said,
- 1:17Speaker 3: you know, they've been studying a Pelas for over a
- 1:19Speaker 3: year now. They thought it was overvalued by the market.
- 1:22Speaker 3: They say, they think what they are paying for this
- 1:24Speaker 3: company is quote a good price. But shares of a
- 1:27Speaker 3: Pellas of one hundred and thirty six percent.
- 1:29Speaker 2: There's a lot of m and out there. Let's do
- 1:32Speaker 2: enough for this and a lot of biotech kind of
- 1:34Speaker 2: exactly names I can't pronounce.
- 1:37Speaker 3: I'm not going to that's what we just say. It's
- 1:39Speaker 3: a drug, it's a medicine.
- 1:42Speaker 2: Brave this with Nathan, What did I all the different
- 1:45Speaker 2: names say.
- 1:46Speaker 3: Crazy that you were listening at so early in the morning.
- 1:48Speaker 3: Thank you so Sentessa so sticking with this pharma situation,
- 1:54Speaker 3: this theme here, We've got shares of Sintessa up forty
- 1:57Speaker 3: six percent. Eli Lilly will pay thirty eight dollars a
- 2:01Speaker 3: share in cash for UK based sent Tessa. That's a
- 2:04Speaker 3: thirty eight percent premium to yesterday's closing price. And here's
- 2:08Speaker 3: something interesting the way they structured this deal, sent Tessa
- 2:11Speaker 3: investors are going to receive CVRs. These are contingent value
- 2:15Speaker 3: rights worth up to an additional nine dollars a share,
- 2:18Speaker 3: bringing the total deal to about seven point eight billion dollars.
- 2:21Speaker 3: And those CVRs are going to be contingent upon the
- 2:23Speaker 3: company hitting certain milestones right including future FDA approvals for
- 2:27Speaker 3: some drugs. Eli Lilly is up just about one percent,
- 2:31Speaker 3: but again sent Tessa up forty six percent on that deal.
- 2:34Speaker 3: And well, let's move over to technology and move out
- 2:36Speaker 3: of pharma space for a moment. Talk about Marvel Technology.
- 2:40Speaker 3: This stock is up nine percent here in the pre
- 2:42Speaker 3: market after Nvidia said it's going to invest two billion
- 2:46Speaker 3: dollars in the chips and networking companies. So in Video
- 2:49Speaker 3: is going to take a stake in Marvel. It's part
- 2:51Speaker 3: of a collaboration that will allow customers to use components
- 2:55Speaker 3: from both of these companies to develop semi custom AI infrastructure.
- 3:00Speaker 3: So it's a deal that Wall Street seems to be applauding,
- 3:03Speaker 3: with Marvel up, like I said, about nine percent here
- 3:05Speaker 3: in the pre market. Guys.
- 3:07Speaker 1: The Stockmovers report from Bloomberg Radio check back with us
- 3:12Speaker 1: throughout the day for the latest roundup of companies making
- 3:14Speaker 1: news on Wall Street, and for the latest market moving headlines.
- 3:18Speaker 1: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
- 3:22Speaker 1: dot com, and on Applecarplay and Android Auto with the
- 3:25Speaker 1: Bloomberg Business app.